SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that tighter debt markets could force failures and consolidation among neocloud providers has fueled concern about NBIS and the wider AI-infrastructure sector. Traders debate whether Nebius is better positioned because of its financing and customer commitments, or still exposed to sector-wide funding and data-center return risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that many neocloud providers could fail or consolidate, alongside his dismissal of buying one, has intensified selling in CoreWeave; traders are also focused on its debt-heavy expansion and access to financing. Bears see those risks as serious, while bulls argue AI-compute demand, customer commitments, and Nvidias backing could support the business.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN and other AI neocloud stocks are under pressure amid Elon Musks warning that many operators could fail or consolidate, alongside broader concerns about debt-heavy expansion and tightening financing. Traders debate whether those risks threaten IREN or whether Musk is talking down competitors; bullish posters point to IRENs customer contracts and ongoing demand for AI compute.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazils market selloff after Lula da Silvas unexpected runoff victory over Flvio Bolsonaro is driving attention, as traders weigh political and economic uncertainty against the view that the drop may be an overreaction and a buying opportunity. Some expect further downside, while others are looking to add exposure.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is caught in a selloff across AI data-center and neocloud stocks, with traders focused on Elon Musks warnings about tighter financing and failures among smaller operators, alongside broader concerns over debt-heavy expansion. Bearish voices fear those risks could affect APLD, while bulls argue its contracted projects, financing and insider buying distinguish it from weaker players.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A volatile week ahead of the Fed decision and major tech earnings has traders split on direction: some expect a relief bounce as the no-strike signal on Iran and lower oil ease geopolitical concerns, while others point to recent weakness and AI-spending worries as reasons for caution.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

A sharp selloff across AI data-center and neocloud stocks, amplified by Elon Musks warnings about tighter debt financing and stranded compute, is driving CIFR discussion; the recent convertible-note financing and dilution are also weighing on sentiment. Traders debate whether CIFRs power-and-data-center landlord model and contracted HPC business distinguish it from GPU-focused neoclouds, while others worry about execution, financing, and further downside.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martins stronger-than-expected quarterly results, raised outlook, record backlog and multiyear F-35 production framework are driving attention, with traders focused on the post-earnings rally. The reaction is broadly bullish, though some warn the sharp move may be overextended and debate whether gains will hold.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMP is drawing attention amid a sharp selloff and volatile price action, with traders split between buying the dip and warning that it continues to underperform other crypto assets. Bulls point to its capped supply and Compounds institutional-finance push, including a reported treasury-funded program and planned product upgrades, as reasons for a potential recovery; bears remain unconvinced.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a tech and AI pullback, as traders debate whether debt-funded AI infrastructure spending is sustainable ahead of major tech earnings and the Fed decision. Bears warn of more downside, while dip-buyers expect a rebound; Iran and oil headlines are adding to market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech And AI Stocks Deliver Fresh Catalysts, as Investors Swarm into Growth Stories

Today's market action highlighted a familiar theme across the small-cap landscape: investors continue searching for transformative growth stories amid a market increasingly driven by company-specific catalysts. $TGNT, $TOVX, $MGNI, $PPCB, $MASK

Rogan’s Runners Market Ignites

The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,

Regulatory Wins, Capital Flows, and Global Expansion Drive Market Momentum

A wave of regulatory clarity, strategic financing, and global expansion is reshaping pockets of the market, with companies across biotech, mobility, and emerging healthcare infrastructure positioning for outsized growth. $MGRX, $TOVX, $ZYBT, $FFAI, $TGNT

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

Others

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong

Equity

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy. 

TOVX Stock Jumps 30% As New Patent, FDA Designation Boost Investor Sentiment

Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children.

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.

Theriva Biologics Inc

Neutral Sentiment

Shares of Theriva Biologics fell sharply after the company priced a public offering of up to 6.8 million shares of common stock and accompanying warrants at $1.10 per unit.&nbsp;The offering is expected to raise nearly $7.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.&nbsp;The warrants will be exercisable immediately at the same price of $1.10 per share and will expire in five years.Theriva shares closed at $0.81, down 41% on Wednesday. After hours, shares dropped to $0.75, reflecting a further 7.4% decline.The offering follows the announcement of positive topline results from the Virage Phase 2b clinical trial, which evaluated VCN-01 in combination with standard chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (PDAC).&nbsp;The study, which included 96 newly diagnosed metastatic PDAC patients, showed that patients receiving VCN-01 plus chemotherapy had a median overall survival (OS) of 10.8 months, compared to 8.6 months in the control group receiving chemotherapy alone.&nbsp;Additionally, the VCN-01+chemotherapy arm showed a median duration of response (DoR) of 11.2 months, double that of the control arm’s 5.4 months.Theriva intends to use the proceeds primarily for working capital, general corporate purposes, and research and development.&nbsp;A portion of the funds may also be used for manufacturing scale-up or potential acquisitions, although no specific deals are currently in place.&nbsp;A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.On Stocktwits, sentiment was described as ‘extremely bullish’, with ‘high’ message volume fueling speculation about the company’s future.&nbsp;One user speculated that a buyout could still be in play, potentially happening before September 30. This user noted that while the offering would dilute the stock, buying at current levels could offer significant upside in the event of a buyout.<stembedurl>https://stocktwits.com/exwallstcfo/message/613861348</stembedurl>Another user drew comparisons between Theriva and Pasithea Therapeutics, suggesting that both companies had positive news followed by public offerings.&nbsp;The user speculated that the offering could have been strategically timed to benefit from a price pump.<stembedurl>https://stocktwits.com/Staceykyusa/message/613855430</stembedurl>Shares of Theriva have fallen nearly 51% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.

Pasithea Therapeutics Corp

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.196
Prev Close	$0.19
Open	$0.19
Dividend Yield	0.00%
50-Day Moving Average	$0.2286
Beta	1.14
Avg. Volume	472,025.95
PE Ratio	-0.29

52-Week High	$0.492
52-Week Low	$0.1628
Market Capitalization	$8.99M
EPS (Annual)	-$2.08
Price to Book	0.74
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TOVX Fundamentals